Yijue Xue
Overview
Explore the profile of Yijue Xue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang M, Liu J, Liao X, Yi Y, Xue Y, Yang L, et al.
Redox Biol
. 2023 Oct;
67:102931.
PMID: 37866161
Cancer cells frequently exhibit aberrant redox homeostasis and adaptation to oxidative stress. Hence abrogation of redox adaptation in cancer cells can be exploited for therapeutic benefit. Here we report SGK3...
2.
Wang M, Xue Y, Shen L, Qin P, Sang X, Tao Z, et al.
Redox Biol
. 2019 May;
24:101225.
PMID: 31136958
Cervical cancer has poor prognosis and patients are often diagnosed at advanced stages of the disease with limited treatment options. There is thus an urgent need for the discovery of...
3.
Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, et al.
EBioMedicine
. 2019 Mar;
43:225-237.
PMID: 30898650
Background: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve...
4.
Xiao Z, He Y, Liu C, Xiang L, Yi J, Wang M, et al.
Oncol Rep
. 2019 Mar;
41(5):2667-2678.
PMID: 30896884
Uterine serous carcinoma (USC) is a subtype of endometrial cancer. Compared with endometrial endometroid carcinoma, the majority of USC cases are more aggressive. Cyclin-dependent kinase inhibitor 2A (P16INK4A) is a...
5.
Ding J, Wang X, Zhang Y, Sang X, Yi J, Liu C, et al.
Cancer Lett
. 2018 Oct;
440-441:54-63.
PMID: 30315845
Selective phosphatidylinositol 3 kinase (PI3K) inhibitors are being actively tested in clinical trials for ERα-positive (ER+) breast cancer due to the presence of activating PIK3CA mutations. However, recent studies have...